PD-1/PD-L1 axis in lung cancer Journal Article


Authors: Santini, F. C.; Hellmann, M. D.
Article Title: PD-1/PD-L1 axis in lung cancer
Abstract: Cancer immunotherapies have revolutionized the treatment of non-small cell lung cancer. Yet, only a small subset of patients will benefit from PD-1 or PD-L1 blockade. PD-L1 tumor cell expression is the only approved biomarker at present. Tumor mutational burden and other emerging biomarkers should improve patient selection. Combination therapy approaches with chemotherapy or cytotoxic T-lymphocyte-associated protein 4 blockade may increase the proportion of patients who benefit from immunotherapy. Although use of immunotherapy in lung cancers with targetable oncogenes has not been particularly successful, the benefit of PD-(L)1 inhibitors in early-stage disease is emerging. This review briefly describes the evolution of the clinical development and future directions of PD-(L)1 blockade in patients with lung cancers. Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.
Keywords: review; advanced cancer; cancer combination chemotherapy; drug efficacy; monotherapy; antineoplastic agent; cancer immunotherapy; lung cancer; tumor marker; oncogene; immunotherapy; cytotoxic t lymphocyte; immunomodulating agent; programmed death 1 ligand 1; programmed death 1 receptor; nsclc; randomized controlled trial (topic); phase 2 clinical trial (topic); phase 3 clinical trial (topic); phase 1 clinical trial (topic); tumor immunogenicity; human; priority journal; anti-pd-1; anti-pd-l1
Journal Title: The Cancer Journal
Volume: 24
Issue: 1
ISSN: 1528-9117
Publisher: Lippincott Williams & Wilkins  
Date Published: 2018-01-01
Start Page: 15
End Page: 19
Language: English
DOI: 10.1097/ppo.0000000000000300
PROVIDER: scopus
PMCID: PMC5784856
PUBMED: 29360723
DOI/URL:
Notes: Review -- Export Date: 1 March 2018 -- Source: Scopus
Altmetric Score
MSK Authors
  1. Matthew David Hellmann
    163 Hellmann